Eli Lilly and Company (LLY) Stock Grade

About Eli Lilly and Company's fundamentals

Eli Lilly is a large-cap pharmaceutical manufacturer with a market capitalization of $965.1 billion, generating impressive profitability metrics including a 31.7% net margin and 77.8% return on equity. The company is experiencing exceptional revenue growth of 44.7% year-over-year, significantly outpacing typical industry expansion rates. Trading at a P/E ratio of 46.8, the stock reflects market expectations for continued strong earnings growth, though this valuation is notably elevated relative to historical pharma industry standards. The company returns a modest 0.6% dividend yield to shareholders.